Decrease of granulocyte-macrophage colony-forming units during high dose medroxyprogesterone acetate treatment in advanced breast cancer.
We treated 18 post-menopausal women with advanced breast cancer with medroxyprogesterone-acetate 1000 mg p.o. daily. The study of granulocyte-macrophage colony forming units (GM-CFU) performed monthly, and peripheral white blood cell count showed an increase of granulocytes not statistically significant and a progressive decrease of GM-CFU that could protect marrow from chemotherapeutic agents or interfere with the myelosuppression of cytotoxic drugs.
D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology*; D003114:Colony-Forming Units Assay; D005260:Female; D006098:Granulocytes / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D007958:Leukocyte Count / Q000187:drug effects; D008264:Macrophages / Q000187:drug effects / Q000502:physiology*; D008525:Medroxyprogesterone / Q000494:pharmacology / Q000627:therapeutic use*; D008593:Menopause; D013997:Time Factors
D008525:Medroxyprogesterone